Pfizer Seeks FDA Approval for RSV Vaccine in Young Adults

Aiming to become the first RSV vaccine for adults under 60, Pfizer's Abrysvo shows promising trial results.

Pfizer's RSV vaccine, Abrysvo, shows promise in protecting adults aged 18-59 at increased risk of severe RSV disease, aiming to expand its current approval.
The vaccine demonstrated a similar immune response in younger adults to that observed in older adults, with significant increases in neutralizing antibodies.
Pfizer plans to submit data to regulatory authorities, including the FDA, for approval to use Abrysvo in the younger adult demographic.
Competing with GSK's Arexvy, Pfizer's move could make Abrysvo the first RSV vaccine approved for adults under 60.
RSV, a common respiratory virus, poses a higher risk of severe illness in infants, older adults, and those with certain chronic conditions.